… 884 patients were analysable for PFS; 437 in the erlotinib … After a median follow-up of 11·4
months for the erlotinib group … with erlotinib than with placebo: 12·3 weeks for patients in the …

… The potential for combining EGFR TKIs with cytotoxic drugs was initially investigated in four
randomized phase III trials. In these studies, concurrent administration of erlotinib or gefitinib …

… to erlotinib in patients with lung adenocarcinoma. To evaluate the toxicity and efficacy of …
and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II …

… Phase I data showed that erlotinib was well tolerated, with encouraging antitumor activity in
patients … completed and a phase III trial (BR.21) examining erlotinib monotherapy 150 mg/…

… for erlotinib, which extended to the subgroup of patients with PS 2 and 3. On the basis of these
observations, we conducted a randomized phase … of advanced NSCLC patients with PS 2. …

… of erlotinib. The Cancer and Leukemia Group B trial 30406 was a randomized phase 2
clinical trial that investigated erlotinib alone or with carboplatin and paclitaxel in patients with a …

… the earlier randomised phase II study, in which gefitinib and erlotinib showed similar efficacy
… /96) of all enroled patients) or clinically selected populations of patients with NSCLC (Kim et …

Purpose Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

… We conducted this international, randomized phase II trial to prospectively … of erlotinib plus
tivantinib with erlotinib plus placebo among previously treated, EGFR inhibitor–naive patients …

Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …